Localized junctional epidermolysis bullosa

Localized junctional epidermolysis bullosa (localized JEB), also known as junctional epidermolysis bullosa inversa or JEB localisata, is a rare inherited skin fragility disorder belonging to the junctional subgroup of epidermolysis bullosa (EB). In this condition, tissue separation occurs within the lamina lucida of the basement membrane zone at the dermal-epidermal junction, leading to blister formation. Unlike more severe generalized forms of JEB, localized JEB is characterized by blistering that is confined to specific body areas rather than being widespread. Blisters typically appear at sites of friction or minor mechanical trauma, most commonly affecting the hands, feet, elbows, and knees, though some subtypes may preferentially involve intertriginous (skin fold) areas. The condition is caused by pathogenic variants in genes encoding components of the hemidesmosome-anchoring filament complex, including COL17A1 (collagen XVII), LAMA3, LAMB3, and LAMC2 (laminin-332 subunits). These proteins are essential for maintaining adhesion between the epidermis and the underlying dermis. Clinical features include recurrent skin blistering, erosions that generally heal without significant scarring (though atrophic scarring can occur), and in some cases nail dystrophy or dental enamel defects. The severity is generally milder compared to generalized JEB subtypes such as JEB with pyloric atresia or the severe generalized (formerly Herlitz) form. There is currently no cure for localized JEB. Management is supportive and focuses on wound care, blister prevention, infection control, and protection of the skin from mechanical trauma. Proper wound dressings, avoidance of friction, and monitoring for secondary infections are cornerstones of care. Nutritional support may be needed in some patients. Genetic counseling is recommended for affected families. Research into gene therapy and protein replacement strategies is ongoing for various forms of EB, offering hope for future targeted treatments.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Localized junctional epidermolysis bullosa